id:"swepub:oai:lup.lub.lu.se:9abe4610-4ea7-4e4c-b6f5-7013e2b32a96"
Search: id:"swepub:oai:lup.lub.lu.se:9abe4610-4ea7-4e4c-b6f5-7013e2b32a96" > Clinical studies of...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Hermans, CedricSaint-Luc University Hospital (author)
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
- Article/chapterEnglish2022
Publisher, publication year, extent ...
- Elsevier BV,2022
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:9abe4610-4ea7-4e4c-b6f5-7013e2b32a96
- https://lup.lub.lu.se/record/9abe4610-4ea7-4e4c-b6f5-7013e2b32a96URI
- https://doi.org/10.1016/j.critrevonc.2022.103678DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- This review compares the methodology of published clinical studies investigating the extended-half-life (EHL) factor VIII (FVIII) products, rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®), BAY 94-9027 (damoctocog alfa pegol, Jivi®), BAX 855 (rurioctocog alfa pegol, Adynovate®) and N8-GP (turoctocog alfa pegol, Esperoct®) including the phase 2/3 studies, A-LONG (NCT01181128), PROTECT VIII (NCT01580293), PROLONG-ATE (NCT01736475) and pathfinder2 (NCT01480180), respectively, and their corresponding pediatric studies and extensions. Study results are interpreted from a treating physician's perspective, translating into evidence-based, real-life use of the different EHL recombinant FVIII products for personalized prophylaxis. The similarities between the studies include methodology, objectives, study design and cohort size. The differences include duration, prophylactic dosing intervals, number of patient arms, use of control group and randomization, and treatment allocation. Comparing these studies broadens physicians’ understanding of each treatment's applicability. Further evaluation of study data and future real-world studies should help physicians to confidently individualize and select treatment for each patient.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Hälsovetenskap Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi hsv//swe
- MEDICAL AND HEALTH SCIENCES Health Sciences Health Care Service and Management, Health Policy and Services and Health Economy hsv//eng
- Extended-half-life
- Factor VIII
- Fc fusion
- Hemophilia A
- Polyethylene glycol
- Prophylaxis
Added entries (persons, corporate bodies, meetings, titles ...)
- Reding, Mark T.University of Minnesota Medical School (author)
- Astermark, JanLund University,Lunds universitet,Institutionen för translationell medicin,Medicinska fakulteten,Department of Translational Medicine,Faculty of Medicine(Swepub:lu)medf-jas (author)
- Klamroth, RobertVivantes Humboldt Hospital (author)
- Mancuso, Maria ElisaHumanitas Research Hospital (author)
- Saint-Luc University HospitalUniversity of Minnesota Medical School (creator_code:org_t)
Related titles
- In:Critical Reviews in Oncology/Hematology: Elsevier BV1741040-8428
Internet link
Find in a library
- Critical Reviews in Oncology/Hematology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hermans, Cedric
- Reding, Mark T.
- Astermark, Jan
- Klamroth, Robert
- Mancuso, Maria E ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Health Sciences
- and Health Care Serv ...
- Articles in the publication
- Critical Reviews ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
